Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.

NCT03356860 is registered in ClinicalTrials.gov with Grand Hôpital de Charleroi as lead sponsor.

NCT NCT03356860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03356860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.
Lead sponsor
Grand Hôpital de Charleroi
Phase
Phase 1/2
Overall status
Completed
Start date
April 13, 2017
Completion date
December 31, 2023
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, luminal b, triple negative breast cancer